Antibodies to human IL-1beta

Details for Australian Patent Application No. 2001295490 (hide)

International Classifications

Event Publications

16 June 2005 Application Accepted

Published as AU-B-2001295490

13 October 2005 Standard Patent Sealed

26 August 2010 Extension of Term of Standard Patents

Novartis AG The earliest first regulatory approval date provided by the patentee 10 May 2010 For the goods ILARIS canakinumab Address for service in Australia: Davies Collison Cave 1 Nicholson Street Melbourne VIC 3000

27 January 2011 Extension granted

Novartis AG The earliest first regulatory approval date provided by the patentee 10 May 2010 For the goods ILARIS canakinumab Extension of Term of patent pursuant to Section 77 expires on 10 May 2025

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.